Search Results
133 results
Your search is now limited to «Biogen» expert search. 01/07/2019 15:51
Biogen Inc. ( BIIB - Free Report) announced two strategic collaborations to develop potential therapies for Alzheimer’s disease, Parkinson’s disease and other devastating neurological diseases.
More from
BioPharma Dive 01/07/2019 08:58
The Skyhawk deal, which covers multiple sclerosis, spinal muscular atrophy and additional neurological disorders, gives Biogen the option to license, develop and commercialize selective RNA-modulating small molecule therapies resulting from the collaboration.
More from BioPharma Dive:
ENDPOINTS 01/04/2019 11:04
C4, meanwhile, will help Biogen identify targets in Alzheimer’s, Parkinson’s and other diseases, and provide the tech to tag these disease-causing proteins for destruction by the cell’s innate degradation mechanism, according to Michael Ehlers, EVP of R&D at Biogen.
More from ENDPOINTS:
NASDAQ 01/04/2019 07:53
The agreement grants Biogen an exclusive license to worldwide intellectual property rights on research-stage therapeutic candidates for the treatment of multiple sclerosis, spinal muscular atrophy and additional neurological disorders.
More from NASDAQ:
PR Newswire 01/04/2019 07:31
Investors should consider this cautionary statement, as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the Securities and Exchange Commission.
More from PR Newswire:
GlobeNewswire 01/04/2019 07:30
Biogen and C4T will research potential targets together and Biogen will advance candidates for development and potential commercialization.
More from GlobeNewswire: 01/03/2019 08:09
Study will provide the first randomized, controlled efficacy and safety data of every-six-week dosing for natalizumab CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- The first patient has been enrolled in a global Phase 3b study evaluating the efficacy and safety of extended interval dosing (EID; every six weeks) for natalizumab compared to standard interval dosing (SID) in patients with relapsing multiple sclerosis (MS), Biogen Inc. (Nasdaq: BIIB) announced.
More from
Seeking Alpha 12/23/2018 13:15
My last article looked at Biogen's (BIIB) controversial Alzheimer's Disease (AD) drug, BAN2401, shortly after Biogen first released initial results back in early July.
More from Seeking Alpha:
24/7 Wall Street 12/21/2018 09:15
Biogen Inc. (NASDAQ: BIIB) was started with a Buy rating at BTIG Research.
More from 24/7 Wall Street:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications